Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.
Previous research identified high levels of the enzyme plasma kallikrein in patients with diabetic macular edema, a condition that can cause impaired vision or blindness. JDRF-funded studies by KalVista Pharmaceuticals aim to identify new therapies that will reduce levels of plasma kallikrein and preserve the eyesight of people with T1D.
Consistent with its leadership role in T1D research, JDRF is prioritizing the investigation of biomarkers. We are advancing the knowledge about the direction and needs of research in this critical area, with the goal of providing vital information to reliably measure or predict disease progression in individuals with T1D and to indicate their responsiveness to therapies. Supporting the development of biomarkers for T1D could provide industry with tools to allow for more efficient and attractive incentives to pursue therapies for the disease.
by Thania Benios For people with type 1 diabetes (T1D) awaiting an islet transplant, a single phone call could change their life. The waiting list for these transplants stretches on, and far too often only serendipity propels a patient to the front of the line. These transplanted islets hold the promise of supplying a patient […]
JDRF-funded scientists are conducting new research to create a blood test that may reveal when beta cells are lost during the development of type 1 diabetes (T1D). The test, which is the first of its kind, could be used to identify individuals who have begun to develop T1D, but do not yet have abnormally high […]
The JDRF Artificial Pancreas Project has significantly accelerated progress toward the delivery of the first artificial pancreas (AP) systems to people with diabetes. Research progress has been exceptional with multiple studies in controlled settings demonstrating that AP systems can significantly reduce high and low blood sugar levels automatically. For people with diabetes to realize the […]
By Thania Benios Since its discovery in 1921, insulin has been called one of the few miracle drugs, having saved countless lives from an otherwise incurable disease. Yet 90 years later, treating and managing type 1 diabetes (T1D) is still a tricky business. Insulin, a hormone, is crucial to life. Without it, glucose cannot move […]
Consider a cluster of immature beta cells that are packaged in a device. The device is then implanted under the skin of a person with diabetes. Over time, the cells develop into functional islets. The end result: insulin production and blood glucose regulation. When JDRF announced its support of ViaCyte this month—an important step was […]
Could metformin, one of the most widely used drugs for type 2 diabetes, help to protect heart health and reduce complications in people with type 1 diabetes (T1D)? JDRF is funding a new trial to answer these questions. The REMOVAL study (REducing with MetfOrmin Vascular Adverse Lesions in T1D)—one of the largest trials targeted at […]
A hormone called GLP-1 has long been thought to have a positive impact on beta cell survival, and now scientists have started to uncover how it works. The new findings provide scientists with insights to improve the effects of currently available drugs that may prevent beta cell loss and promote beta cell survival in people with T1D or in those in the transplant setting.